| Vol. 13.19 – 20 May, 2021 |
| |
|
|
| Researchers established a noncanonical function for small nuclear ribonucleoprotein polypeptide A′ (SNRPA1) and a previously unknown RNA structural code that regulated alternative splicing, and found that this SNRPA1-mediated pathway acted as a promoter of breast cancer metastasis. [Science] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators demonstrated that the loss of the lysine 9 of histone H3 methyltransferase G9a in the mammary epithelium resulted in de novo chromatin opening, aberrant formation of the mammary ductal tree, impaired stem cell potential, disrupted intraductal polarity, and loss of tissue function. [Cell Stem Cell] |
|
|
|
| Researchers described a role for the Bcl-2 family member BAD in postnatal mammary gland morphogenesis that involves controlling localized translation and cell migration during gland development. [Nature Communications] |
|
|
|
| The authors suggested MutL loss as a predictive marker of sensitivity to combinatorial treatment with endocrine intervention and HER inhibitors in endocrine treatment-resistant ER+/HER2− breast cancer patients. [Nature Communications] |
|
|
|
| Investigators uncovered a dual role for Rank in the mammary epithelia: Rank induced senescence and stemness, delaying tumor initiation but increasing tumor aggressiveness. [Developmental Cell] |
|
|
|
| Scientists generated mice that produced an RFP-marked ERα+ mammary gland epithelial cell lineage to investigate ERα dependencies and their implications during breast cancer growth and metastasis. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| The authors investigated the contribution of nucleoside diphosphate kinase (NME1), a known metastasis suppressor, to local invasion in breast cancer. [Oncogene] |
|
|
|
| Scientists investigated the role of Ubiquitin-Specific Protease 22 (USP22) in HER2-driven breast cancer (HER2+-BC) and demonstrated that USP22 was required for the tumorigenic properties in murine and human HER2+-BC models. [Oncogene] |
|
|
|
| Investigators studied the interaction between Notch receptors (Notch1-4) and PTEN, and demonstrated that Notch3 inhibited breast cancer proliferation and suppressed tumorigenesis by transactivating PTEN expression. [Cell Death & Disease] |
| | The authors examined intracellular levels of let-7f in 4T1 mammary carcinoma cells to test the hypothesis that let-7f released from human mesenchymal stem cells may be incorporated by tumor cells. [Cell Death & Disease] |
|
|
|
| Scientists developed a bispecific antibody simultaneously targeting both PD1 and HER2 in an attempt to combine HER2-targeted therapy with immune checkpoint blockade for treating HER2-positive solid tumors. [Acta Pharmacologica Sinica] |
|
|
|
| Researchers hypothesized that by creating an MHC independent vaccination, they would give rise to a sustained immune response against CD133 in triple negative breast carcinomas. [Molecular Therapy-Oncolytics] |
|
|
|
| Scientists showed that inhibition of miRNAs – 503 and – 23a, alone or in combination, enhanced tumor proliferation in vitro. [Scientific Reports] |
|
|
|
|
| The authors examine potential links between Aurora-A stabilisation and localisation, and discuss them in the perspective of a more effective targeting of Aurora-A in cancer therapy. [Oncogene] |
|
|
|
| Researchers discuss the biological functions of protein arginine methyltransferases (PRMTs) in cancer and the current development status of PRMT inhibitors in cancer therapy. [Experimental & Molecular Medicine] |
|
|
|
|
| Novartis is continuing to support Dana-Farber Cancer Institute’s development of transformative medicines to address current and future needs in cancer care, including research on TNBC resistance to CDK4/6 inhibitors. [Dana-Farber Cancer Institute] |
|
|
|
|
| July 8 – 10, 2021 Boston, Massachusetts, United States |
|
|
|
|
|
| Louisiana State University – New Orleans, Louisiana, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| Bristol Myers Squibb – Redwood City, California, United States |
|
|
|
| The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
|